Cost-Effectiveness of Adding Human Papilloma Virus Testing to a Managed Care Cervical Cancer Screening Program
Authors:
- Neal M. LonkyNLNeal M. Lonky
- Mark I. HunterMHMark I. Hunter
- Mashod SadeghiMSMashod Sadeghi
- Gary EdwardsGEGary Edwards
- Kathy BajamundiKBKathy Bajamundi
- Bradley J. MonkBMBradley J. Monk
- 1 October 2007
- journal article
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 11 (4) , 258-264
Abstract
The purpose of this study was to demonstrate a methodology for auditing the impact of HCII testing on the direct cost of cervical cancer cytological screening, where the test is collected in all women screened and processed routinely in women age 30 years and older. After a policy change to screen all patients 30 years or older with both Pap smears and high-risk human papillomavirus (HR-HPV), as well as cocollection of HR-HPV in women younger than 30 years, all cytological, HPV, and histological data pertaining to cervical screening was collected retrospectively during a 2-month period. We documented the direct costs of performing these tests and estimated the necessary compliance rate for balanced cost-effectiveness. During the 2-month period, 8,300 women were screened with both Pap smear and HPV cocollection. Of the 'nonnormal' cytological findings, 5% of patients showed either atypical squamous cells (3.5%) or squamous intraepithelial abnormalities (1.5%). An additional 427 (5%) patients had the finding of positive HR-HPV with normal cytology. Six of these patients opted for immediate colposcopy, 2 of which were found to have cervical intraepithelial neoplasia 2. In women age 30 years and older, 900 patients per 1,000 screened would be eligible for a 2-year screening interval based on negative cytology and negative HR-HPV. Based on the direct costs associated with this cohort, no more than 164 women could request screening at an interval shorter than 3 years for the total costs of such a program to equal that of one without HR-HPV cocollection. By adding HCII collection to the Pap smear for our entire screening cohort, we intended to reduce the number of tests performed, which was impacted by its age distribution. Our findings indicate that at least 736 of the 900 double-negative patients (82%) would have to be screened at no less than 3 years for such a screening paradigm to be cost-effective in managing women 30 years and older.Keywords
This publication has 14 references indexed in Scilit:
- Human Papillomavirus Testing in Primary Cervical Screening and Abnormal Papanicolaou ManagementObstetrical & Gynecological Survey, 2006
- HPV testing in cervical screeningBest Practice & Research Clinical Obstetrics & Gynaecology, 2006
- Cost-Effectiveness Analysis Based on the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS)JNCI: Journal of the National Cancer Institute, 2006
- Human Papillomavirus Triage of Atypical Squamous Cells of Undetermined Significance: Cost-Effective, But At What Cost?JNCI: Journal of the National Cancer Institute, 2006
- A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screeningInternational Journal of Cancer, 2005
- Cost‐effectiveness of liquid‐based cytology with or without hybrid‐capture II HPV test compared with conventional Pap smears: A study by the French society of clinical cytologyDiagnostic Cytopathology, 2005
- 2001 Consensus Guidelines for the Management of Women With Cervical Cytological AbnormalitiesJAMA, 2002
- Risks for Incident Human Papillomavirus Infection and Low-Grade Squamous Intraepithelial Lesion Development in Young FemalesJAMA, 2001
- Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort studyThe Lancet, 2001
- Natural History of Cervicovaginal Papillomavirus Infection in Young WomenNew England Journal of Medicine, 1998